NCT04863885View on ClinicalTrials.gov

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

April 11, 2026

Study Completion Date

October 31, 2027

Conditions
Metastatic Urothelial Carcinoma
Interventions
DRUG

Ipilimumab

Participants will receive Ipilimumab 3 mg/kg

DRUG

Nivolumab

Participants will receive Nivoumab 1mg/kg

DRUG

Sacituzumab govitecan

Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER